Clinical characteristics
As shown in Table 1, 70 (23.5%) GTN patients were older than 40 years.
Antecedent pregnancy was molar pregnancy in 227 (76.2%) GTN patients.
The interval from antecedent pregnancy to chemotherapy was ≥12 months in
10% of cases. Pre-therapy serum β-hCG was
>105 IU/L in 9.7% of patients. More than
8 metastases were observed in 14.8% of cases and 8.4% of the patients
had previously had two- or multiple-agent chemotherapy failure. Tumor
size including uterus was more than 5 cm in 9.7% of patients.
Liver and brain metastases were observed in 1.3% and 2.7% of patients,
respectively. Lung metastases was found in 60.1% of patients, followed
by kidney metastases in 0.3%. According to the FIGO 2021 staging
system, 37.9% of GTN cases were classified as stage I, 1.7% as stage
II, 56% as stage III, and 4.4% as stage IV. A total of 18 patients
were defined as the ultra-high-risk group according to the FIGO Cancer
Report 2021 (ultra-high-risk subgroup: FIGO score >12, as
well as patients with liver, brain, or extensive metastases)6.